Lyndra Therapeutics, Inc.

MA · Founded 2015 · Biotech · Defunct

3D-printed oral drug delivery systems with gastric residence technology for sustained release over extended periods

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · lyndra.com

Sector: Biotech
Headquarters: MA
Founded: 2015
Latest Form D: $123M, Dec 2023
Total capital: $268M

Federal grants: $3.7M; 6 awards · 2016–2020; Rank in peer group#8 of 18
Private capital raised: $265M; 5 Form D · last Dec 2023; 34 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 9; 28 pending · first 2023; Rank in peer group#2 of 18

Capital timeline

Latest events

Dec 2023Private capital raisedForm D · SEC · 5th filing$123M
Jun 2023Private capital raisedForm D · SEC · 4th filing$20.4M
Jun 2021Private capital raisedForm D · SEC · 3rd filing$60.5M
Mar 2020Federal grantHealth and Human S · Phase II · A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy$1M
Jan 2019Private capital raisedForm D · SEC · 2nd filing$55.2M
Jul 2018Federal grantHealth and Human S · Phase II · An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$452K
Sep 2017Federal grantHealth and Human S · Phase I · Novel D Printed Architectures for Oral Long acting Drug Delivery Systems$225K
Jul 2016Private capital raisedForm D · SEC · 1st filing$5.9M

Show 3 earlier federal awards

Sep 2017Federal grantHealth and Human S · Phase I · Novel 3D Printed Architectures for Oral Long-acting Drug Delivery Systems$225K
Aug 2017Federal grantHealth and Human S · Phase II · An Oral Ultra Long-Acting Ivermectin for Malaria Elimination$1.5M
Aug 2016Federal grantHealth and Human S · Phase I · An Oral Long-Acting Doxycycline for Onchocerciasis Eradication: Process Improvement for Small Batch Manufacturing$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 18 peers

Line = median

Biotech · Device

Federal grants#8 · top 44%
Granted patents#2 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Amy SchulmanDirectorNamed in SEC Form D filings
Ashish Giovanni SinghDirectorNamed in SEC Form D filings
Carlo Giovanni TraversoDirectorNamed in SEC Form D filings
Carlo Giovanni TraversoDirectorNamed in SEC Form D filings
Catherine ReynoldsDirectorNamed in SEC Form D filings
Doug Giovanni DachilleDirectorNamed in SEC Form D filings

Show all 14 people

Helene Giovanni MadonickDirectorNamed in SEC Form D filings
Jessica Giovanni BallingerExecutive OfficerNamed in SEC Form D filings
Jillian Moo-YoungDirectorNamed in SEC Form D filings
Patricia HurterExecutive Officer, DirectorNamed in SEC Form D filings
Robert Giovanni LangerDirectorNamed in SEC Form D filings
Robert S. LangerDirectorNamed in SEC Form D filings
Zafi AvnurDirectorNamed in SEC Form D filings
Zafi S. AvnurDirectorNamed in SEC Form D filings

What it has protected

USPTO · 9 granted of 37

Oct 21, 2025GrantedCapsules And Capsule Coatings For Gastric Residence Dosage FormsUSPTOUS 12,447,130
Apr 8, 2025GrantedEncapsulation Of Gastric Residence SystemsUSPTOUS 12,268,776
Nov 12, 2024GrantedStomach Simulating DeviceUSPTOUS 12,142,158

Show all 37 patent records

Capsules And Capsule Coatings For Gastric Residence Dosage FormsOct 21, 2025 · US 12,447,130Granted
Encapsulation Of Gastric Residence SystemsApr 8, 2025 · US 12,268,776Granted
Stomach Simulating DeviceNov 12, 2024 · US 12,142,158Granted
Gastric Residence Systems Comprising MethadoneOct 10, 2024 · Application 18289326Pending
Materials Architecture For Gastric Residence SystemsOct 8, 2024 · US 12,109,305Granted
Gastric Residence Systems With Release Rate-modulating FilmsJul 2, 2024 · US 12,023,406Granted
Geometric Configurations For Gastric Residence SystemsMay 28, 2024 · US 11,992,552Granted
Encapsulation Of Gastric Residence SystemsOct 24, 2023 · US 11,793,751Granted
Gastric Residence Systems For Sustained Release Of Therapeutic Agents And Methods Of Use ThereofFeb 14, 2023 · US 11,576,859Granted
Gastric Residence Systems For Sustained Delivery Of Adamantane-class DrugsFeb 14, 2023 · US 11,576,866Granted
Gastric Residence Systems Having Arms With Controlled Stiffness For Improved Gastric ResidenceDec 8, 2022 · Application 17774445Pending
Systems For Enteric Delivery Of Therapeutic AgentsJul 1, 2021 · Application 17268405Pending
Dosage Forms For Gastric RetentionApplication 63301041Pending
Suture Configurations For Gastric Residence SystemsApplication 63572128Pending
Gastric Residence Systems Comprising Buprenorphine And NaloxoneApplication 63184734Pending
Gastric Residence Systems For Administration Of RisperidoneApplication 63174497Pending
Gastric Residence Systems For Administration Of RisperidoneApplication 63139299Pending
Gastric Residence Systems Having Arms With Controlled Stiffness For Improved Gastric ResidenceApplication PCTUS2020059534Pending
Formulations For Release-rate Modulating Films For Gastric Residence SystemsApplication PCTUS2020059536Pending
Gastric Residence Systems For Administration Of Active AgentsApplication PCTUS2020059541Pending
Gastric Residence Systems Having A Filament For Improved Gastric ResidenceApplication PCTUS2020059533Pending
Polymeric Linkers For A Gastric Residence SystemApplication PCTUS2020059537Pending
Coatings For Gastric Residence Dosage FormsApplication PCTUS2020023710Pending
Capsules And Capsule Coatings For Gastric Residence Dosage FormsApplication PCTUS2020023704Pending
Stomach Simulating DeviceApplication PCTUS2019064309Pending
Gastric Residence Systems Comprising MethadoneApplication 63184760Pending
Suture Configurations For Gastric Residence SystemsApplication 63567323Pending
Risperidone Dosage Regimens With Gastric Residence SystemsApplication PCTUS2023075648Pending
Metal Cores For Gastric Residence SystemsApplication PCTUS2023071617Pending
Manufacturing Methods For Gastric Residence SystemsApplication 63506039Pending
Dosage Forms For Gastric RetentionApplication PCTUS2023060931Pending
Risperidone Dosage Regimens With Gastric Residence SystemsApplication 63377961Pending
Metal Cores For Gastric Residence SystemsApplication 63370366Pending
Dosage Forms For Gastric RetentionApplication 63368605Pending
Gastric Residence Systems Comprising Buprenorphine And NaloxoneApplication PCTUS2022072114Pending
Gastric Residence Systems Comprising MethadoneApplication PCTUS2022072115Pending
Gastric Residence Systems For Administration Of RisperidoneApplication PCTUS2022013027Pending

Revere Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
Sienna BiopharmaceuticalsSimilar federal contract value in Biotech · null in contracts
Vima TherapeuticsSimilar federal contract value in Biotech · null in contracts
Triveni BioSimilar federal contract value in Biotech · null in contracts
First Light Biosciences Inc.Similar federal contract value in Biotech · null in contracts
jCyte, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.